35 results about "Immune complex formation" patented technology

The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2 / neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid.

A process for preparing a patient-specific immunoadsorber, which comprises (i) extracting a body fluid from a patient having an immunopathological condition, the fluid containing immune complexes that are relevant to that immunopathological condition, (ii) contacting the extracted fluid with an adsorbent for the immune complexes to form adsorbed immune complexes, (iii) eluting the adsorbed complexes to form an eluate, (iv) fractionating the eluate into a plurality of immune complex component fractions, and (v) immobilizing the immune complex components on one or more biologically compatible carriers activated to bond to its surface one or more desired immune complex components.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample.

The invention relates to a method for the immunodetection of human blood group antibodies, particularly relating to a method and a used detection strip for rapidly detecting human blood group antibodies. The method comprises the following steps: a blood group antigen is precoated on a solid-phase carrier; the blood group antigen with a signal mark is fixed on a fiber mat adhered on one end of the carrier; and a sample is added dropwise, if the sample to be detected contains an antibody which can be combined with the blood group antigen, a macroscopic immune complex can be observed on the solid-phase carrier, and otherwise, the macroscopic immune complex is not formed, thus the blood group antibody in the sample is detected.

A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

A method is disclosed for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, cocaine, methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to the surface of a solid support in a preselected pattern to form an array wherein the locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample.

The invention relates to an improved test method for solid phase fluorescence immunity. The invention is characterized in that the supplied eluent can be utilized to mark the immune complex and form a dissociation labeled substances, and the testing of the dissociation labeled substances can be carried on. The solute of the eluent is a negative ion surface active agent SDS, and the menstruum of the eluent is the water or Tris aqueous solution; and according to a chemical cross-linking or physical adsorption method, a dissociation labeled substances is formed, the sensitivity of the test is improved. The invention solves the pollution problem of lanthanon ion in the solid phase time-resolved fluorescence immunity, the drying craft in the prior art is spurned, and the repetitiveness and stability of the test are improved.

The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2 / neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.

The invention discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 15-30 parts of buffalo horn sheets, 20-30 parts of oldenlandia diffusa, 10-20 parts of radix rehmanniae, 10-15 parts of fructus forsythiae, 10-20 parts of radix paeoniae alba, 10-20 parts of cortex moutan, 10-15 parts of gentiana macrophylla, 15-20 parts of lalang grass rhizome and 10-15 parts of fried atractylodes macrocephala. The invention also discloses a preparation method and application of the traditional Chinese medicine composition for treating systemic lupus erythematosus. According to the formula, the traditional Chinese medicine composition has the favorable effects of inhibiting the generation of an autoantibody, forming an immune complex and inhibiting type-III allergic reaction, has favorable analgesic and anti-inflammatory effects, has a remarkable effect in clinical treatment and has a better effect as comparison with preliminarily-researched Langchuangqing granules, in addition, the formula is simple, the dosage is reduced, and caulis sinomenii serving as a poisonous traditional Chinese medicine in the formula is removed, so that the traditional Chinese medicine composition prepared according to the formula has more advantages from the views of safety and effectiveness as comparison with the Langchuangqing granules.

The invention discloses a cadmium-chelated immune complex as well as a preparation method and an application thereof. The cadmium-chelated immune complex is one of the following complexes: a complex formed by binding cadmium to an immune complex; or a complex formed by binding cadmium to a carrier protein and an antibody which can specifically bind to the carrier protein; or a complex formed by binding cadmium to immune globulin and then binding to a carrier protein. The cadmium-chelated immune complex is an immune complex having relative specificity and is used for detecting the cadmium-chelated immune complex and the content thereof in serum of people in an area to directly reflect the cadmium pollution degree of the area or not.

The invention provides a lead-chelated immune compound, and a preparation method and an application of the lead-chelated immune compound. The lead-chelated immune compound is one of the following compounds: a compound formed from an immune compound combined with lead ions, or a compound formed from carrier protein combined with lead and an antibody specifically binding to the carrier protein, or a compound formed from immune globulin combined with lead ions and carrier protein. The lead-chelated immune compound is an immune compound with relative specificity. Whether the lead-chelated immune compound is contained in serum of people in an area and the content of the compound is detected, so that the lead pollution degree in the area is indirectly reflected.

A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention provides an arsenic-chelated immune compound, and a preparation method and an application of the arsenic-chelated immune compound. The arsenic-chelated immune compound is one of the following compounds: a compound formed from an immune compound combined with arsenic ions, or a compound formed from carrier protein combined with arsenic and an antibody specifically binding to the carrier protein, or a compound formed from immune globulin combined with arsenic and carrier protein. The arsenic-chelated immune compound is an immune compound with relative specificity. Whether the arsenic-chelated immune compound is contained in serum of people in an area and the content of the compound are detected, so that the arsenic pollution degree in the area is indirectly reflected.

The invention discloses a mercury-chelated immune complex, a preparation method and an application thereof. The mercury-chelated immune complex is one from the following complexes: 1) a complex formed by combining mercury ion to an immune complex; 2) a complex formed by combining mercury ion to a carrier protein with an antibody capable of being specially combined with the carrier protein; or 3) a complex formed by combining mercury ion to an immune globulin and then combining the immune globulin with the carrier protein. The mercury-chelated immune complex has a relative specificity and is used for detecting whether human serum in people in a certain region contains mercury or not and detecting the content of mercury, thereby indirectly reflecting mercury pollution degree of this region.

The present invention provides a FcγRIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immune complex formation aberrant immune complex clearance and immune complex induced inflammation. This invention also provides means of using this model to treat or prevent autoimmune disease.

The invention discloses a nickel chelate immune-complex and its preparation method and application. The nickel chelate immune-complex is one of the following complexes: a complex formed by binding nickel ion to an immune-complex, or a complex formed by binding nickel ion to a carrier protein and an antibody specifically binding to the carrier protein; or a complex formed by binding nickel ion to immune globulin and binding the nickel ion bound to the immune globulin to carrier protein. The nickel chelate immune-complex can be used in detecting whether serum of people in a region contains the nickel chelate immune-complex and detecting content of the nickel chelate immune-complex so as to indirectly reflect nickel pollution degree of the region.

The invention discloses an arsenic chelating type immune compound. The arsenic chelating type immune compound is selected from one of the following compounds: the compound formed by binding arsenic ions and the immune compound; or, the compound formed from the arsenic ions bound with vector protein and an antibody specifically bound with the vector protein; or, the compound formed by binding the arsenic ions with immune globulin and then binding with the vector protein. The invention also discloses a preparation method of the arsenic chelating type immune compound with excellent effect. The preparation method comprises the following steps of S1, preparing a chelating agent solution; S2, preparing a vector protein solution; S3, stirring and staying overnight; S4, dialyzing; S5, adding the arsenic ions; S6, recycling the waste solution; S7, specifically binding. The preparation method has the characteristics that the application range is broader, the cost is reduced, the dialyzing rate is increased, the preparation cycle is shortened, the energy-saving and environment-friendly effects are realized, and the chemical pollution is avoided; the market competitiveness is larger.

The invention discloses a lead cheating type immune complex with excellent effect. The lead cheating type immune complex with excellent effect is selected from any of complexes, such as a complex which is formed by binding lead ions with an immune complex; or, a complex which is formed by binding lead ions with carrier protein and then binding with an antibody which is specifically bound with thecarrier protein; or, a complex which is formed by binding lead ions with immune globulin and then binding with the carrier protein. The invention also discloses a preparation method of the lead cheating type immune complex with excellent effect. The preparation method comprises the following steps of S1, preparing a chelating agent solution; S2, preparing a carrier protein solution; S3, stirring and staying overnight; S4, dialyzing; S5, adding the lead ions; S6, recycling waste liquid; S7, specifically binding. The lead cheating type immune complex with excellent effect has the characteristicsthat the application range is broader, the cost is reduced, the dialysis rate is increased, the preparation cycle is shortened, and the energy-saving and environment-friendly effects are realized; the chemical pollution is avoided; the market competitiveness is larger.

The invention relates to an in vitro method of screening immunogenic peptides of interest, capable of recognizing antibodies originating from the serum of individuals suffering from active tuberculosis, said method comprising: bringing into contact of peptides of the serum originating from patients suffering from active tuberculosis, detecting the formation of immune complexes in the preceding step, and selecting peptides of interest for which the value of a ratio R is greater than or equal to 1.5, the ratio R being the measurement value of the formation of immune complex to the measurement value obtained from the control sample.

The invention discloses a good-effect mercury chelating type immune complex. The good-effect mercury chelating type immune complex is one of the following complexes: a complex formed by binding mercury ions with an immune complex, a complex formed by binding the mercury ions with an antibody which is in specific binding with carrier protein after binding the mercury ions with the carrier protein or a complex formed by binding the mercury ions with the carrier protein after binding the mercury ions with immune globulin. The invention also discloses a preparation method of the good-effect mercury chelating type immune complex. The preparation method comprises the following steps: S1, preparing a chelating agent solution; S2, preparing a carrier protein solution; S3, stirring and staying overnight; S4, carrying out dialysis treatment; S5, adding the mercury ions; S6, carrying out recovery treatment on waste liquid; S7, carrying out specific binding. The preparation method disclosed by theinvention is wider in application range, the cost can be saved, the dialysis rate is increased, a preparation period can be shortened, the preparation method also has the characteristics of energy conservation and environment protection, chemical pollution can be prevented from being caused, and an environment protection effect is good.

The invention provides an arsenic-chelated immune compound, and a preparation method and an application of the arsenic-chelated immune compound. The arsenic-chelated immune compound is one of the following compounds: a compound formed from an immune compound combined with arsenic ions, or a compound formed from carrier protein combined with arsenic and an antibody specifically binding to the carrier protein, or a compound formed from immune globulin combined with arsenic and carrier protein. The arsenic-chelated immune compound is an immune compound with relative specificity. Whether the arsenic-chelated immune compound is contained in serum of people in an area and the content of the compound are detected, so that the arsenic pollution degree in the area is indirectly reflected.

The invention discloses a cadmium chelate type immune complex with excellent effect. The cadmium chelate type immune complex refers to one of the following complexes: a complex formed from cadmium ions by binding with an immune complex; a complex formed from the cadmium ions and an antibody specifically binding with a carrier protein after the cadmium ions bind with the carrier protein; a complexformed from the cadmium ions by binding with an immune globulin and a carrier protein sequentially. The invention further discloses a preparation method of the cadmium chelate type immune complex withthe excellent effect. The method comprises the following steps: S1, preparing a chelating agent solution; S2, preparing a carrier protein solution; S3, performing stirring overnight; S4, performing dialysis treatment; S5, adding the cadmium ions; S6, recovering waste liquor; S7, performing specific binding. The method is wider in application range, cost can be saved, dialysis rate is increased, preparation period can be shortened, the method further has the characteristics of being energy-saving and environmentally friendly, chemical pollution is avoided, and the environmental protection effect is good.